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Abstract
Background: PCA3 and TMPRSS2-ERG are commonly overexpressed biomarkers in prostate cancer, but reports have
emerged demonstrating altered expression also in areas outside the tumour foci in cancerous prostates. Our aim
was to measure PCA3 and TMPRSS2-ERG expression systematically in all regions of prostate cross-sections, matching
the data to corresponding tissue morphology.
Methods: TMPRSS2-ERG and PCA3 mRNA levels were measured with quantitative reverse-transcription PCR assays in
270 samples from cross-sections of five radical prostatectomy specimens. ERG expression was examined by
immunohistochemistry.
Results: TMPRSS2-ERG mRNAs were detected in three patients and in 15 tissue samples in total. These included two
carcinoma samples and 13 histologically benign samples, eight of which were located next to malignant tumours
or PIN (prostatic intraepithelial neoplasia) lesions and five of which did not reside in the vicinity of any evident
carcinoma foci. ERG protein expression was limited to areas of TMPRSS2-ERG mRNA expression, but did not identify
all of them. PCA3 expression was detected in all five cross-sections, with statistically significant, three-fold higher
expression in carcinoma regions.
Conclusions: TMPRSS2-ERG expression was detected in carcinoma foci, regions next to them, and in samples not
adjacent to carcinoma foci. Claimed as a cancer-associated phenomenon, this fusion gene measurement could, if
validated with a larger cohort, be utilized as an addition to histological analysis to predict current or future cancer
risk in men with negative biopsies. Molecular changes outside the carcinoma foci are also indicated for PCA3, as its
expression was only moderately increased in the carcinoma regions.
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Background
The proposed idea of field cancerization – phenomenon
first described by Slaughter and colleagues in 1953 [1] –
comprises the assumption that in cancers, originally a lar-
ger area of the tissue than merely the tumour focus can be
changed due to inherent mutations or environmental fac-
tors. The hypothesis has been supported by several studies
reporting molecular level alterations not only in the carcin-
oma tissue of an organ containing a malignant tumour, but
also in the area outside the cancerous region [2, 3]. Both
aberrant protein expression and mRNA transcript levels
have been described [4]. Besides providing an interesting
perspective to understanding carcinogenesis, detectable
consequences of the field effect phenomenon could be
used to supplement diagnostics.
Prostate cancer is a disease with a growing incidence
and a heterogeneous nature, and the heterogeneity of the
disease has made diagnostics and prognostics challenging.
The currently used biomarker, PSA (prostate specific anti-
gen) measured from blood, cannot reliably confirm the
presence of cancer in the prostate since increased levels
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are frequently found also in other prostatic diseases such
as hyperplasia and prostatitis. Present routine to establish
the prostate cancer diagnosis is based on the histological
examination of core needle biopsies that are taken with
trans-rectal ultrasound guidance. However, the biopsy
cores represent a random sampling of the overall tumour
load regarding the aiming of the biopsy needle to the esti-
mated carcinoma location. A histologically benign biopsy
result leads to a negative cancer diagnosis, but based on
the previous reports on molecular level alterations in
cancer-adjacent tissues, it may be premature in determin-
ing the status of the patient.
Alterations in the expression of prostate cancer
marker candidate genes TMPRSS2-ERG (transmembrane
protease, serine 2; ETV-related gene) and PCA3 (pros-
tate cancer antigen 3) have previously been detected by
us and others [5–9]. The changes were specifically seen
in the histologically benign areas of cancerous prostates
but not in similar areas of prostates that were free of
clinical cancer. This study was designed to systematically
locate the regions of differential expression of these
genes in single cross-sections of five cancerous prostates
and evaluate whether the location of the carcinoma was
associated with TMPRSS2-ERG or PCA3 mRNA levels
or ERG protein expression.
Methods
Sample collection
To measure the mRNA expression of the target genes
by quantitative reverse-transcription PCR (qRT-PCR) in
prostate tissue, prostate cross-sections covering the en-
tire organ were obtained fresh from five prostates
(hereafter referred to as prostates A, B, C, D, and E)
from men undergoing robotic assisted laparoscopic rad-
ical prostatectomies due to prostate cancer at Turku
University Hospital, Turku, Finland in June–September
2013. Five consecutive patients with previous diagnosis
of prostatic adenocarcinoma in transrectal biopsies
were enrolled in the study. Patients with diagnosed
adenocarcinoma in both lobes and patients with clinical
suspicion of multifocal or large tumour were excluded
from the study. The sample collection protocol is
depicted in Fig. 1. Briefly, a horizontal tissue slice of
2 mm in thickness was removed from each prostate
and further cut into 5x5x2 mm pieces systematically
with sterile blades, avoiding cross-contamination be-
tween pieces. A Styrofoam plate with a 5x5 mm grid
was used to record the two-dimensional location of
each piece, resulting in a unique coordinate code for
each piece of tissue. Depending on the size of the
organ, this procedure yielded 48 individual samples for
prostate A, 62 samples for prostate B, 44 samples for
prostate C, 55 samples for prostate D, and 61 samples
for prostate E. All pieces were stored separately in
RNAlater RNA Stabilization Reagent (Qiagen, Hilden,
Germany) at −20 °C.
Tissue immediately adjacent to the tissue cross-section
used in mRNA measurements was fixed in formalin and
embedded in macro paraffin blocks (FFPE) to enable
examination of tissue morphology. Sections were cut
directly from the superior and inferior side of the cross-
section used in mRNA measurements, stained with
hematoxylin and eosin (HE), and inspected for cancer
foci and prostatic epithelial neoplasia (PIN) lesions by an
experienced uro-pathologist. The locations of carcinoma
areas and PIN lesions were marked and the slides were
scanned into digital images. All five prostate cross-
sections contained cancerous areas and cross-sections B
and C contained also PIN lesions.
The study protocol was approved by the Ethics Com-
mittee of the Hospital District of Southwest Finland and
it was in accordance with the Helsinki Declaration of
1975, as revised in 1996, with written informed consent
obtained from each participant.
Fig. 1 Flowchart of the sample collection protocol for mRNA experiments. A horizontal cross-section slice of 2 mm in thickness was cut from the
middle of each prostate and laid flat on a cutting plate while recording the original orientation of the slice in the organ. The slice was further cut
into 5x5 mm pieces according to a grid and each sample was stored separately in an RNA stabilizer solution
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Real-time PCR for PCA3 and TMPRSS2-ERG mRNAs
RNA extraction and reverse transcription were performed
with RNeasy Mini kit (Qiagen, Germany) and High Cap-
acity cDNA Archive kit (Applied Biosystems, USA)
according to manufacturer’s instructions and as described
previously [10]. Artificial internal standard RNA was
added to each sample at the beginning of RNA extraction
process, after cell lysis [11].
Quantitative real-time PCR assays using a closed-tube
concept [12] and time-resolved fluorometry-based detec-
tion were performed as described previously [9, 10] to
measure PCA3 and TMPRSS2-ERG mRNA levels in each
tissue piece. Levels of KLK3 (kallikrein-related peptidase
3, gene encoding PSA) mRNA and internal standard RNA
were also measured for control and normalization pur-
poses [11–14]. The oligonucleotide sequences are pre-
sented in Table 1. External DNA standards (Table 2) were
used to form a standard curve and the lowest dilutions
equal the limits of detection for the particular assays.
Immunohistochemistry
For immunohistochemistry (IHC) experiments, sections
of 3–4 μm were cut from the FFPE tissue macro blocks
immediately from the superior and inferior side of the
HE-stained sections. The sections were pretreated in
xylene and ethanol, and the heat-induced antigen
retrieval was performed in a microwave oven using Tar-
get Retrieval Solution (Dako) followed by cooling at RT.
Staining was performed by incubating the slides for one
hour at RT in a humid chamber with rabbit monoclonal
ERG antibody (clone EPR3864; Epitomics) that was used
in 1:250 dilution. EnVision™ +Dual Link System-HRP
(Dako) was used as the secondary antibody with a 30-min
incubation at RT. The staining was visualized by
incubation in DAB+ Chromogen solution (Dako) for
10 min at RT. After counterstaining with
hematoxylin, dehydration, and treatment by xylene,
the slides were analysed by an experienced uro-
pathologist. The vascular endothelial cells served as
Table 1 Sequences of the primers and probes used in this study
Oligonucleotide Sequence (5’- > 3’) GenBank database sequence number Position in sequence
KLK3
5’ primer TGA ACC AGA GGA GTT CTT GAC X05332 523–543
3’ primer CCC AGA ATC ACC CGA GCA G X05332 667–685
reporter probe CCT TCT GAG GGT GAA CTT GCG C X05332 596–617
quencher probe AAT CAC CCT CAG AAG G X05332 600–601, 604–617
mmPSA
5’ primer TGA ACC AGA GGA GTT CTT GCA X05332 523–543
3’ primer CCC AGA ATC ACC CGA GCG A X05332 667–685
reporter probe CCT TCT GAG GGT GAT TGC GCA C X05332 594–601, 604–617
quencher probe AAT CAC CCT CAG AAG G X05332 600–601, 604–617
PCA3
5’ primer GGT GGG AAG GAC CTG ATG ATA C AF103907 95–116
3’ primer GGG CGA GGC TCA TCG AT AF103907 505–521
reporter probe AGA AAT GCC CGG CCG CCA TC AF103907 478–497
quencher probe CCG GGC ATT TCT AF103907 478–489
TMPRSS2-ERG III
5’ primer TAG GCG CGA GCT AAG CAG GAG NM_005656.3 4–24
3’ primer GTA GGC ACA CTC AAA CAA CGA CTG G NM_004449.4 338–362
reporter probe AGC GCG GCA GGA AGC CTT ATC AGT T NM_005656.3 and NM_004449.4 57–64 and 310–326
quencher probe TTC CTG CCG CGC T NM_005656.3 and NM_004449.4 57–64 and 310–314
TMPRSS2-ERG VI
5’ primer CGG CAG GTC ATA TTG AAC ATT CC NM_005656.3 73–95
3’ primer GCA CAC TCA AAC AAC GAC TGG NM_004449.4 338–358
reporter probe CTT TGA ACT CAG AAG CCT TAT CAG TTG TGA NM_005656.3 and NM_004449.4 139–149 and 312–330
quencher probe GGC TTC TGA GTT CAA AG NM_005656.3 and NM_004449.4 139–149 and 312–317
Lanthanide chelates were attached to the 5’ ends of the reporter probes via an amino group to enable signal measurement with time-resolved fluorescence and
phosphate groups to the 3’ ends to prevent them from functioning as starting points for DNA synthesis. Quencher molecules were attached to the 3’ ends of the
quencher probes. The oligonucleotide sequences have been previously published for KLK3 [12, 13], mmPSA [11–13], PCA3 [10, 20], TMPRSS2-ERG III [9, 21, 22], and
TMPRSS2-ERG VI [9] assays
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positive controls for the staining with ERG antibody
and cells of the benign glands as the negative control.
Data analysis
The specific locations of tissue were translated to match
samples used for mRNA measurements by dividing the
digital images of HE-stained tissue slides into equal
amount of regions. Thus, potential shrinkage of the tis-
sue was accounted for on average. Each sample piece
was given coordinates on two axis (one giving values
from A to K, and the other giving values from 1 to 10).
Samples were classified into four categories based on
morphology-based examination of the immediately ad-
jacent HE-stained tissue. Sample was deemed as a
carcinoma sample if one or both studied HE sections
revealed adenocarcinoma at the same location, and
PIN if one or both studied HE sections revealed PIN
lesion. If both studied HE sections contained only
histologically benign tissue in that area but the sam-
ple immediately next to the sample was classified as
carcinoma or PIN sample, the sample was classified
as “histologically benign tissue immediately adjacent
to a carcinoma/PIN sample” (HBAC). If HE sections
showed only histologically benign tissue in the sample
and the samples next to it, sample was marked as
histologically benign area (HB).
Samples were considered to contain measurable
amounts of target mRNAs only when three PCR repli-
cates gave a rise in fluorescence signals. Copy numbers
were calculated as previously described [10], taking into
account the potential RNA loss in extraction by using an
internal RNA standard. For TMPRSS2-ERG mRNAs,
samples that produced signal in only one or two out of
the three PCR replicates were considered as samples
where TMPRSS2-ERG mRNA expression was detectable
but not quantifiable. Limits of detection for the real-
time PCR assays are presented
Mann–Whitney U test was used to study associations
between mRNA and protein expression of the target
genes and the histology of the tissue (SPSS 20.0, IBM).
Results
Patient and tumour characteristics
The essential clinicopathological characteristics of the five
cases are presented in Table 3. All cases were clinically
and pathologically organ confined. Two patients (B and
D) had 5-alpha-reductase inhibitor therapy and one pa-
tient (E) had a combination therapy of 5-alpha-reductase
inhibitor and α1 receptor antagonist prior to surgery. No
positive margins were detected and all patients achieved
serum PSA of <0.1 ng/mL postoperatively. Using ultrasen-
sitive PSA measurement, two patients had detectable post-
operative serum PSA (0.004 and 0.026 ng/mL). During the
follow-up of 8–11 months, none of the patients had expe-
rienced clinical or biochemical recurrences. Patients D
and E had clearly one index tumour, patients A and C had
two or more carcinoma foci (between 6 and 18 mm), and
patient B had two small, well-differentiated carcinoma foci
(both <10 mm).
KLK3 mRNA expression
KLK3 mRNA levels were measured from all samples for
control purposes. There were no statistically significant
differences in KLK3 mRNA levels between carcinoma,
PIN, HBAC, or HB samples (data not shown).
PCA3 mRNA expression
All five prostates showed PCA3 mRNA expression. It
was universally expressed in prostates A and B and in
80–96 % of samples of prostates C, D, and E. When all
samples from the five prostates were combined, the me-
dian expression level was highest (9.54 × 105 mRNA
copies/μg total RNA) in the samples that were classified
as carcinoma samples, second highest in PIN samples,
third highest in samples adjacent to carcinoma or PIN
samples, and lowest in HB samples (2.62 × 105 mRNA
Table 2 Dilutions of external DNA standards used in the real-time PCR assays
Range (molecules per mL of template)
Target RNA Lowest concentration Highest concentration Total number of points on standard curve
KLK3 2.5 × 103 2 × 1011 8
PCA3 1.3 × 103 2.5 × 1011 7
TMPRSS2-ERG III 5 × 103 5 × 107 4
TMPRSS2-ERG VI 2 × 104 2 × 108 4
Table 3 Characteristics of the five patients included in the
study
Patient Age PSA (ng/mL) Gleason sum Tumour
volume (%)
preoperative postoperative
A 67 4.5 <0.003 3 + 4 10
B 59 9.2 <0.003 3 + 3 2
C 59 8.5 <0.003 3 + 4 5
D 67 16 0.026 4 + 3 8
E 66 18 0.004 4 + 3 15
Tumour volume in the whole prostate was estimated based on the macro
sections taken every 5 mm and covering the whole organ
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copies/μg total RNA (Fig. 2). The statistically significant
difference in median PCA3 mRNA values between carcin-
oma samples and HB samples was 3.6-fold (p < 0.001).
The difference between carcinoma samples and samples
adjacent to carcinoma or PIN was 3.1-fold (p < 0.001).
When the five studied prostate cross-sections were
looked at individually, the same trend of statistically
significantly higher PCA3 mRNA expression in carcin-
oma areas persisted only for prostate C, where the
difference between medians of carcinoma and HB sam-
ples was 20-fold (p < 0.003), and for prostate D with a
5.2-fold difference (p < 0.001).
TMPRSS2-ERG mRNA expression
TMPRSS2-ERG III mRNA was detected in 3 out of 5
prostates (B, C, and E) and TMPRSS2-ERG VI mRNA in
2 out of 5 prostates (prostates C and E). The samples
containing detectable TMPRSS2-ERG expression and
their location in relation to carcinoma areas are depicted
in Fig. 3. Reliably quantifiable expression of TMPRSS2-
ERG III or VI mRNAs was found in four histologically
benign samples, two of which were HBAC samples. The
third sample was located next to a PIN lesion and the
fourth resided in an area that was regarded as histologi-
cally benign. In addition, detectable but not quantifiable
expression of these mRNAs was found in one carcinoma
focus of prostate C, one carcinoma sample of prostate E,
in four HBAC samples, and in five HB samples. One of
the HB samples was adjacent to a PIN area. None of the
individual samples showed simultaneous expression of
both TMPRSS2-ERG mRNA isoforms.
ERG protein expression
IHC experiments detected positive ERG staining only in
prostate C (Fig. 4). Based on the morphological analysis,
all ERG positive areas contained carcinoma tissue.
TMPRSS2-ERG mRNA was detectable in one out of the
four individual tissue samples matching the ERG positive
areas and the other three samples were located adjacent
to TMPRSS2-ERG mRNA positive samples. One of the
samples contained TMPRSS2-ERG III mRNA and the
others TMPRSS2-ERG VI mRNA, but the amounts were
not quantifiable in any of them. Areas in the same and
other prostates containing either quantifiable or only de-
tectable expression of TMPRSS2-ERG mRNAs were
negative for ERG in IHC.
Discussion
Field effect is a recognized phenomenon in several can-
cers, including prostate cancer. It suggests that larger
areas of the tissue than just the histologically identifiable
tumour regions are changed on the molecular level. We
studied the extent and location of the mRNA expression
of two suggested prostate cancer markers, TMPRSS2-ERG
fusion gene and PCA3, in a systematic way in cross-
sections of cancerous prostates containing both histologi-
cally benign and carcinoma areas.
In addition to overexpression in tumours, increased
expression of PCA3 has been described also in areas
adjacent to carcinoma foci and the phenomenon was
explained by a carcinogenic field effect [3]. The thus far
reported findings of TMPRSS2-ERG in BPH (benign
prostatic hyperplasia) tissue, or in a benign area from a
cancerous prostate, have sometimes been speculated to
result from small carcinoma foci that resided in sampled
tissues and were unnoticed despite microscopic examin-
ation [5, 7]. Also the possibility of the samples contain-
ing precancerous tissue has been proposed [6, 7]. Our
previous study, showing that 44 % of the histologically
benign sampled areas of cancerous prostates contained
TMPRSS2-ERG mRNA transcripts in contrast to none of
the seven benign tissues of cancer-free prostates [9], led
us to hypothesize on TMPRSS2-ERG expression not
being limited to carcinoma foci in cancerous prostates.
The fusion gene mRNAs were detectable in two carcin-
oma samples in this study, and also in 13 histologically be-
nign samples. However, eight of the TMPRSS2-ERG
positive histologically benign samples resided immediately
next to samples classified as carcinoma or PIN. Due to the
sample collection set-up, those samples could also contain
cancer cells originating from the adjacent sample areas as
the protocol of matching tissue morphology with the loca-
tion of samples used for mRNA measurements was not
Fig. 2 PCA3 mRNA levels in tissue samples from the five studied
prostates. The boxes contain interquartile ranges with median values
shown as horizontal lines and the whiskers extending to minimum
and maximum values. The statistical outliers are depicted with circles
and negative samples with open diamonds. Statistically significant
differences between the sample groups are marked with stars, and
three stars denote a p value of less than 0.001. HB, histologically
benign samples; HBAC, histologically benign samples adjacent to
carcinoma; PIN, prostatic intraepithelial neoplasia
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able to fully account for site-specific tissue shrinkage
caused by the fixation of the tissue. Yet we detected
TMPRSS2-ERG expression in five samples without evi-
dence of carcinoma foci in the immediate vicinity. In con-
trary to our previous study [9], none of the individual
samples in this limited cohort showed simultaneous ex-
pression of both studied TMPRSS2-ERG isoforms. The de-
tection rate in cancerous samples was also higher, 66 %, in
the previous study, which could potentially be due to the
sampling protocol which was more laborious and time-
consuming in this study, potentially leading to RNA deg-
radation and thus lower detection rates.
The tissue regions that were positively stained in ERG
IHC matched the locations of carcinoma lesions, and
either contained detectable TMPRSS2-ERG mRNA or
were located adjacent to samples that did. However, all
Fig. 3 Location of detected TMPRSS2-ERG mRNA expression and ERG protein expression in relation to carcinoma areas. Morphologically
determined carcinoma areas are marked with C in the five prostates. Dark blue boxes denote samples with quantifiable TMPRSS2-ERG III mRNA
expression, and light blue boxes represent samples with detectable but not quantifiable TMPRSS2-ERG III mRNA expression. Red boxes denote
samples with quantifiable TMPRSS2-ERG VI mRNA expression and light orange boxes represent detectable but not quantifiable TMPRSS2-ERG VI
mRNA expression. Yellow boxes denote ERG protein expression. TMPRSS2-ERG mRNAs were found in prostates B, C, and E and ERG protein
expression only in prostate C. None of the samples showed simultaneous expression of both TMPRSS2-ERG mRNA variants
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TMPRSS2-ERG mRNA positive areas did not stain posi-
tively for ERG even within a specific prostate, suggesting
that the mRNA assays can reveal additional suspicious
areas compared to IHC methods alone. This could be
due to the IHC-negative areas not producing such
amounts or forms of ERG protein that the antibody rec-
ognizes, even though previous reports of it have demon-
strated correct identification of all the samples with the
TMPRSS2-ERG rearrangement [15]. The rearrangement
variant type did not seem to play a role in identifying
ERG protein expression.
PCA3 is a non-coding gene that does not produce a
functional protein, so its expression was studied only on
the mRNA level. PCA3 is reported to be 10–100-fold
overexpressed in prostate tumours [16, 17], but in our
previous studies, we have seen values of this magnitude
only when carcinomas were compared to prostates with-
out clinical prostate cancer [9] and a 5.8-fold increase of
PCA3 expression in tumours was observed when they
were compared to benign areas of cancerous prostates
[8]. In this cross-section study, we detected a three times
higher expression in the carcinoma samples than in the
histologically benign areas next to malignant tumours or
at locations further away. It would therefore seem that
the increase in PCA3 mRNA expression is not limited to
the carcinoma foci in a cancerous prostate, but rather
that there is a more global field change.
The set-up of this study is admittedly of a preliminary
and experimental nature and due to the small size of the
cohort, the conclusions can only be suggestive. The fact
that only approximately half of prostate cancer cases are
TMPRSS2-ERG positive [18] contributed to the even
smaller number of TMPRSS2-ERG positive cases in our
study. Additionally, we only studied one section of each
prostate here in order to ensure the reliability of the rou-
tine pathological diagnostic procedure. This, however,
could limit the conclusions drawn considering that pros-
tate cancer, as also was seen in these specimens, is often a
multifocal disease. The neoadjuvant therapy administered
to three of the patients could also have had an effect on
the results. However, despite these limitations, we find the
set-up of this study novel and of interest. Clark and col-
leagues conducted a similar type of study using prostate
cross-section slices and obtaining samples from cancerous
and nonmalignant areas of the prostate, deemed as such
based on the morphology of the slices above and below
[5]. They, however, only looked at two matched samples
from each prostatectomy specimen instead of the more
systematic approach adopted here, which comprised a sys-
tematic and quantitative examination of mRNA levels
throughout the tissue slice.
Utilizing these findings for diagnostic purposes would
entail qRT-PCR assays performed on biopsies or tissue ma-
terial obtained from transurethral resection of the prostate
(TURP), where a finding of TMPRSS2-ERG mRNAs or
high PCA3 expression would indicate an increased risk of
having or developing prostate cancer. While the routine
formalin fixation may hamper the use of qRT-PCR assays,
the recently introduced, alternative non-crosslinking fixa-
tives such as PAXgene (Preanalytix) could be used for such
purposes [19]. To our knowledge, there have been no re-
ports of the fusion gene detected in tissues of men without
any prostatic disorders, which supports the potential to
use the fusion gene for risk analyses. However, there have
been findings of TMPRSS2-ERG in the tissue of 6–8 %
men with BPH but without history or suspicion of prostate
cancer [5, 7]. This is suggested to be due to the fusion gene
being a sign of early changes in the gland, but not always
leading to malignancy, and naturally means that a positive
TMPRSS2-ERG mRNA test result does not require the
presence of a current prostate carcinoma.
Conclusions
Our systematic study, despite its highly preliminary na-
ture, shows that even though it is rare, it is possible to
detect TMPRSS2-ERG transcripts in cancerous prostates
in areas other than the carcinoma regions. If validated
with larger cohorts and biopsy or TURP material, this
could bring a new additive to assessment of risk of pros-
tate cancer especially in men with negative biopsies.
Fig. 4 Histology of prostate C showing (a) HE staining and (b) immunohistochemical ERG staining from the same area. The nuclei of malignant
glands stain positively for ERG suggesting that ERG is overexpressed due to TMPRSS2-ERG fusion. Scale bar 500 μm
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